Psychiatry & Neurology Doctors in Bradford, PA Accepting Medicare

4 Psychiatry & Neurology doctors found. Showing 1 - 4

Dr. Neeraj Shukla, MD Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 110 Campus Dr, Bradford, PA 16701 Phone: 814-362-6535    Fax: 814-362-7358

Dr. Alexander Welge, M.D. Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 116 Interstate Pkwy, Bradford, PA 16701 Phone: 814-362-8509    Fax: 814-368-7732

Dr. John Felix Simora, D.O. Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 800 E Main St, Bradford, PA 16701 Phone: 814-817-1400

Dr. Dezso J Halbauer, MD Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 110 Campus Dr, Bradford, PA 16701 Phone: 814-362-6535

News Archive

Plexxikon commences patient dosage in PLX4032 trials for metastatic melanoma

Plexxikon Inc. announces that enrollment has been initiated and the first patient has been treated in the first of two pivotal trials of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation occurring in about 50 percent of melanomas and about eight percent of all solid tumors.

White House to announce 2nd renewal for old health plans

Americans who kept health plans that didn't comply with the health law's coverage requirements will be able to renew those policies again, sources tell media outlets. The Obama administration is expected to announce the extension today.

FDA grants QLT's QLT091001 orphan drug designation for treatment of Retinitis Pigmentosa

QLT Inc. today announced that QLT091001, the Company's oral synthetic retinoid, has been granted orphan drug designation for the treatment of Retinitis Pigmentosa (RP) from the U.S. Food and Drug Administration (FDA). This follows the FDA grant of orphan drug designation for QLT091001 for the treatment of Leber Congenital Amaurosis (LCA) also on December 7, 2010.

U.S.-based CRO licenses NewCardio's QTinno software solution for automating cardiac safety analysis

NewCardio, Inc., a cardiac diagnostic technology provider, announced today that a U.S.-based CRO that provides early phase and specialty clinical drug development services to the pharmaceutical industry, has signed an MSA, licensing NewCardio's QTinno™ software solution in order to deliver fully automated cardiac safety analysis in early phase QT studies.

MRC study to monitor Pentosan Polysulphate as a treatment for Creutzfeldt-Jakob disease receives approval

The plans for a monitoring study on patients being treated with Pentosan Polysulphate (PPS) for CJD and variant CJD have received a favourable opinion from the Eastern Multi-Centre Research Ethics Committee. This follows a provisional opinion from the committee in August.

Read more Medical News

› Verified 9 days ago